REGULATORY

Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers

By Ken Yoshino October 9, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s key drug pricing panel on October 8 showed little support for industry demands to abolish “spillover” and “huge-seller” re-pricing rules in the FY2026 reform, with members emphasizing the continued relevance of these mechanisms in controlling healthcare costs. The Ministry…

To read the full story

FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025

REGULATORY

Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
Japan Cabinet OKs Record Social Security Spending in FY2026 Budget, 105 Billion Yen in Drug Price Cuts
December 26, 2025
MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…